The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.
Bruno Daniele
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Massimo Di Maio
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Ciro Gallo
No relevant relationships to disclose
Antonio Gasbarrini
No relevant relationships to disclose
Giacomo Carteni
No relevant relationships to disclose
Giovan Giuseppe Di Costanzo
No relevant relationships to disclose
Antonio Craxi
No relevant relationships to disclose
Giuseppe Cabibbo
No relevant relationships to disclose
Luigi Bolondi
No relevant relationships to disclose
Alessandro Granito
No relevant relationships to disclose
Gabriele Missale
No relevant relationships to disclose
Antonio Frassoldati
No relevant relationships to disclose
Mario Angelico
No relevant relationships to disclose
Mario Roselli
No relevant relationships to disclose
Gennaro Daniele
No relevant relationships to disclose
Francesco Perrone
Honoraria - Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Research Funding - Amgen; Bayer; Roche